for second discuss you for our quarter everyone. of Ryan, you, financial us joining Thank XXXX. Thank today good fiscal afternoon, to the results and
that a diverse stronger Hologic confirmed with than growth much results more bigger, pre-pandemic. now exceptional Our and durable company is
strong forward. of our and a also our poised of the flow strengthened anomalies. this On balance and are that we from strength to We've with carry supply we've fully positive cash was exceptional momentum the harder position operating sheet, and throughout company. spikes this dramatically see are transformation transformation, top of backdrop that chain We said pandemic COVID a and recognize against appreciate to
clouds the clear our shines. to these result robust transformation really As continue of
and total both was share revenue results high was were the For per $X.XX our end guidance. billion the non-GAAP above earnings quarter, $X.XX, of
Before were providing the going for admittedly we comps of and did more no from about it, days, highlights proud last we make the softer two to due which against are quarter, year Omicron very results. selling surge, mistake these the have
our growing and organic of COVID, to and returned with XX%. were by three of a XX.X% powered XX.X%, also deliver excluding performance By Health COVID, XX.X%. out XX.X% growth. to continued First excluding And Surgical and revenue, Breast grew which growing grew Diagnostics posting notable, very nearly again, XX%. diagnostics, two strong divisions most growth, north molecular of division,
the Our to many our incredible outstanding our world elevate would shown be possible. This results colleagues every not up women's to Without and the commitment of throughout our teams strong purpose, execution passion are have pandemic. a promise testament the discipline who of health. day and the to around performance
to our Turning today. themes for
First, diversity provide the our and reinforce durability drivers into and showcase in business. to transformed we'll each division the to insight of growth
the the longer performance growth strong frame Second, we'll the term. to guidance for helping and review outlook fiscal our against year XXXX and of longer-term targets, our remainder
strong now introduction, results. COVID on growth second and stand where reflect our with With that drivers quarter pandemic performance focus we specifically, today, through powering brief we we'll let's close, the excitement and our on look ahead. to the as And our progress our
come of many different pre-pandemic. we business to continue compared where is demonstrate to appreciate the have dramatically that to realize At and we highest were level, you our
growth added more These the innovative and diverse we ahead. relationships strength are deepening do our strategically we customers company that years participate across our top for drivers line within accretive with overall products our more balanced, more services strong will today contributing are in, so growth Through the markets pandemic, and the and We to are durable. we also serve. the to
macro the you environment Diagnostics, to to us While lead Diagnostics deliver. count can present on of continues In multitude a to way. Molecular continues challenges, the
represents XX across Panther over systems, global creates of Panther expanded the tremendous Panthers, combined and the of menu the customers. Panther superior for with differentiates our competition. base division's nearly sustained us for from Our our installed and workflow FDA-approved strong X,XXX assays the The growth. broad Fusion value our catalyst of
we are more adding menu menu positioning throughput on of our performance. labs breadth over full systems time. placing the more As our more and positioned pandemic, continue unlock Panther Fusion systems, and more Panther Hologic well with to are strong our exit we Panthers to
STI of period. Consistent the was BVCVTV by core in with the prior Diagnostics Growth quarters, menu, vaginitis HPV Trich. Clemidiagonrhia, pillars aided including by were diverse and our Molecular growth and panel driven our
more strong menu from had and again on our once the be latter also the expect respiratory nature. in two contributions we where seasonal Fusion, to Panther We of Biotheranostics the
growth to of from combination Health, the Breast quarter. emphatically headwinds, Health considerations Breast for to quarters division chip in positive a four of In returned four after Comp growth, growth posting the factors. semiconductor decline, primarily resulted due aside, the XX.X% supply strong
of the gantries This more chip planned. year continues into than second to availability the for a of the moving allocated gantries half allowing originally back the included the quarter number in semiconductor delivery quarter. First, for improve, of
last well balance and visibility though we and of ahead a below continues result, QX QX of the for gantry anticipate availability to each our strengthen. to chip the delivery as levels QX, As modestly year year, still register
for increase our our the chip despite backlog are of instruments clinically strong, mammography seeing high. And duration demand the differentiated we headwind, in exceptional remains cancellations. Second, and remains order no
the customers. we with our strong as delivered for value of strengthen again our consistently source Third, we revenue service division being in revenue and the QX, service largest relationships demonstrate proposition
portfolio business biopsy navigating Brevera non-chip Somatex to some of headwinds result also needles quarters. an in indication Health interventional returned by faced quarter, Breast the supply form, we such growing of our as the for and This side interventional the strong prior Tumark of success chain the fourth, as our XX.X% And markers. related serves disposable driven
close Health, like partners To opportunity with thank to have chip prioritized take women's purpose aligned to we'd supply have and our out who this our Breast health.
As rather we customers sooner than to to a result, had later. screen and and better quarter, more ability deliver gantries our more positioned confidence the this women projected than are
which partnerships, We also for even and strengthened efforts, innovation for undeniably thankful making stronger are these design our influenced future. the Hologic have
much years as of a the to our stronger different years than growth business us Health, Diagnostics faster globally, While meaningful is Breast bigger, much a business remarkably three last has and for given emerging driver growing. ago. few and has surgical also and attention four transformed been completely to It's during
In management than the QX, NovaSure. system MyoSure more and of Fluent was Surgical and driven XX% by grew portfolio fluid hysteroscopic contributions strong our from
encouraged are yet we quarter for latter, our the the iteration, On by strong latest NovaSure VX. another NovaSure
addition, build to growing driver our larger In and a continues for division. momentum portfolio laparoscopic the into is
for said would we'll the of At deliver move on from the low organic growth guidance growth each our division the year, on fiscal our Now division beginning XXXX, performance we that for drivers the reflect against double-digit year. COVID. excluding to
fiscal we XXXX point of marks pleased halfway our the towards achieving share to the are progress As QX year, goal. the close our
Diagnostics, of year, total great XXXX XX%, initial This double-digit nearly or have grown and division, and fiscal targets. in XX.X% our company X.X%, respectively. exceed us of growth half delivered And organic first puts to low the achieve has by excluding COVID. Health Surgical XX.X%, the shape our Through
will have Surgical, and Diagnostics going much we ahead, forward. Looking tougher comps
in resulting And is the the to the solid By of will true. healthier, for opposite close be comps going year, both last QX numbers, now a Health forward, were due chip divisions stronger Breast phasing of headwind, posting the facing.
Health Breast will 'XX in back fiscal the than comps in Our softer be QX. of half
today long-term for since to Taking XXXX growth as may X% 'XX COVID, is see Now, that of question results, longer-term as due short, with a back, target. projections our expectation our to our is it announced focusing step we through fiscal appropriate. understand rate on year. we on organic our XXXX we goal recent performance that strong double-digit we already unique more very because strong whether the growth In excluding revenue view revenue our impressive we X% believe still growth top some a in
Shifting In generated to COVID. million. we of guidance prior $XX our our exceeding revenue, final QX, topic $XX today, assay million gears in COVID
We are to and resources excited the corner turn to continue business the forward. opportunity for dynamic energy our to further and our drive concentrate
presented. the world's Since we the We thing rose to tests in early the maximize accurate meet needs. high-quality, occasion, opportunities molecular to the highly delivering the start of pandemic XXXX,
storms. flexibility, more on we For return proud. a should capable this, And are we and manufacturing massive Wave's capacity COVID even are operational weathering leaning of expansion future of our extremely
the domestic larger we and accelerated the of health of today. a proud is women's much to a And globe. the years Hologic byproduct, enterprise. as worldwide a more immensely business placements into advance extremely Panther respected global influence stronger also are more largely our brand is recognized is We Today, formidable Hologic across more and which We've business expanded around world.
response our and the strategic pandemic.We diligently R&D driving from thoughtfully our in benefits innovation invested organic acquisitions. business, growth to the With completing through products and adding
to discipline we to the health even ago, R&D, got the during all, while it us adjusting with relatively investments with and marketing maintained our Super sales operational our initiatives And and ad the expense expenses all well business when our today, approach, during ahead Bowl women woman and put it we keeping and precision carefully quarters the ourselves pandemic, versus and encouraging to and through continue initiatives. to year for We Bowl opportunistic important, were of that a made flat return opportunistic investment sponsorship, equally needed COVID and to maintaining prioritize timed discipline. support never strongest revenue, off WTA each affords And after to with marketing ability most, their managed the Super headcount. of WTA world exams
built stronger demonstrate are benefits that of powered pandemic, All maximized where our success transformed years, the ground from the realizing in, bigger, up QX culture over we challenges we the many business We've purpose-driven our results and of is through that opportunity. culture. our fueled by our has our it our
the As has our force transformed into we a time, at are transformed strong result, Hologic and the future. same today
growth is bright. durable path, our future strengthened our have and We
turn me over let to that, With call Karleen. the
